These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 7706779

  • 1. OKT3 treatment for allograft rejection is a risk factor for cytomegalovirus disease in liver transplantation.
    Portela D, Patel R, Larson-Keller JJ, Ilstrup DM, Wiesner RH, Steers JL, Krom RA, Paya CV.
    J Infect Dis; 1995 Apr; 171(4):1014-8. PubMed ID: 7706779
    [Abstract] [Full Text] [Related]

  • 2. Symptomatic cytomegalovirus infection in renal transplant recipients given either Minnesota antilymphoblast globulin (MALG) or OKT3 for rejection prophylaxis.
    Bailey TC, Powderly WG, Storch GA, Miller SB, Dunkel JD, Woodward RS, Spitznagel E, Hanto DW, Dunagan WC.
    Am J Kidney Dis; 1993 Feb; 21(2):196-201. PubMed ID: 8381577
    [Abstract] [Full Text] [Related]

  • 3. Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3.
    Hibberd PL, Tolkoff-Rubin NE, Cosimi AB, Schooley RT, Isaacson D, Doran M, Delvecchio A, Delmonico FL, Auchincloss H, Rubin RH.
    Transplantation; 1992 Jan; 53(1):68-72. PubMed ID: 1310173
    [Abstract] [Full Text] [Related]

  • 4. Increased early mortality in women undergoing cardiac transplantation.
    Wechsler ME, Giardina EG, Sciacca RR, Rose EA, Barr ML.
    Circulation; 1995 Feb 15; 91(4):1029-35. PubMed ID: 7850938
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation.
    Rosen HR, Shackleton CR, Higa L, Gralnek IM, Farmer DA, McDiarmid SV, Holt C, Lewin KJ, Busuttil RW, Martin P.
    Am J Gastroenterol; 1997 Sep 15; 92(9):1453-7. PubMed ID: 9317061
    [Abstract] [Full Text] [Related]

  • 7. Long-term ganciclovir prophylaxis eliminates serious cytomegalovirus disease in liver transplant recipients receiving OKT3 therapy for rejection.
    Winston DJ, Imagawa DK, Holt CD, Kaldas F, Shaked A, Busuttil RW.
    Transplantation; 1995 Dec 15; 60(11):1357-60. PubMed ID: 8525537
    [Abstract] [Full Text] [Related]

  • 8. Combined antiviral and immunoglobulin therapy as prophylaxis against cytomegalovirus infection after heart transplantation.
    Valenza M, Czer LS, Pan SH, Aleksic I, Freimark D, Harasty DA, Admon D, Barath P, Blanche C, Trento A.
    J Heart Lung Transplant; 1995 Dec 15; 14(4):659-65. PubMed ID: 7578172
    [Abstract] [Full Text] [Related]

  • 9. Prevalence of invasive cytomegalovirus disease with administration of muromonab CD-3 in patients undergoing orthotopic liver transplantation.
    Hooks MA, Perlino CA, Henderson JM, Millikan WJ, Kutner MH.
    Ann Pharmacother; 1992 May 15; 26(5):617-20. PubMed ID: 1317228
    [Abstract] [Full Text] [Related]

  • 10. Half dose of OKT3 is efficient in treatment of steroid-resistant renal allograft rejection.
    Midtvedt K, Tafjord AB, Hartmann A, Eide TC, Holdaas H, Nordal KP, Draganov B, Sødal G, Leivestad T, Fauchald P.
    Transplantation; 1996 Jul 15; 62(1):38-42. PubMed ID: 8693541
    [Abstract] [Full Text] [Related]

  • 11. Infections with cytomegalovirus and other herpesviruses in 121 liver transplant recipients: transmission by donated organ and the effect of OKT3 antibodies.
    Singh N, Dummer JS, Kusne S, Breinig MK, Armstrong JA, Makowka L, Starzl TE, Ho M.
    J Infect Dis; 1988 Jul 15; 158(1):124-31. PubMed ID: 2839576
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Efficacy of OKT3 therapy for acute rejection in isolated lung transplantation.
    Shennib H, Massard G, Reynaud M, Noirclerc M.
    J Heart Lung Transplant; 1994 Jul 15; 13(3):514-9. PubMed ID: 8061029
    [Abstract] [Full Text] [Related]

  • 14. OKT3 induction and steroid-free maintenance immunosuppression for treatment of high-risk heart transplant recipients.
    Prieto M, Lake KD, Pritzker MR, Jorgensen CR, Arom KV, Love KR, Emery RW.
    J Heart Lung Transplant; 1991 Jul 15; 10(6):901-11. PubMed ID: 1661608
    [Abstract] [Full Text] [Related]

  • 15. Factors influencing the occurrence of active cytomegalovirus (CMV) infections after organ transplantation.
    Boland GJ, Hene RJ, Ververs C, de Haan MA, de Gast GC.
    Clin Exp Immunol; 1993 Nov 15; 94(2):306-12. PubMed ID: 8222321
    [Abstract] [Full Text] [Related]

  • 16. Major infectious complications after orthotopic liver transplantation and comparison of outcomes in patients receiving cyclosporine or FK506 as primary immunosuppression.
    Hadley S, Samore MH, Lewis WD, Jenkins RL, Karchmer AW, Hammer SM.
    Transplantation; 1995 Mar 27; 59(6):851-9. PubMed ID: 7535482
    [Abstract] [Full Text] [Related]

  • 17. OKT3 escalating dose regimens provide effective therapy for renal allograft rejection.
    Woodle ES, Bruce DS, Josephson M, Cronin D, Newell KA, Millis JM, Piper JB, O'Laughlin R, Thistlethwaite JR.
    Clin Transplant; 1996 Aug 27; 10(4):389-95. PubMed ID: 8884115
    [Abstract] [Full Text] [Related]

  • 18. OKT3 as prophylaxis immunosuppression in pediatric liver transplant recipients.
    Sommerauer JF, Atkison P, Howard J, Grant D, Wall W.
    Transplant Proc; 1994 Feb 27; 26(1):154-6. PubMed ID: 8108917
    [No Abstract] [Full Text] [Related]

  • 19. OKT3 treatment of steroid-resistant rejection in pediatric liver transplant recipients.
    McDiarmid SV, Busuttil RW, Terasaki P, Vargas JH, Ament ME.
    J Pediatr Gastroenterol Nutr; 1992 Jan 27; 14(1):86-91. PubMed ID: 1315386
    [Abstract] [Full Text] [Related]

  • 20. Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomized, double-blind, placebo-controlled trial.
    Snydman DR, Werner BG, Dougherty NN, Griffith J, Rubin RH, Dienstag JL, Rohrer RH, Freeman R, Jenkins R, Lewis WD, Hammer S, O'Rourke E, Grady GF, Fawaz K, Kaplan MM, Hoffman MA, Katz AT, Doran M, Boston Center for Liver Transplantation CMVIG Study Group.
    Ann Intern Med; 1993 Nov 15; 119(10):984-91. PubMed ID: 8214995
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.